Evaluation of Treatment of Chronic HCV Patients in Chronic Kidney Disease Versus End Stage Renal Disease Patients
NCT03341988
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
100
Enrollment
OTHER
Sponsor class
Conditions
Hepatitis C
Interventions
DRUG:
Ombitasvir-Paritaprevir-Ritonavir Tab 12.5-75-50 milligram
Sponsor
Assiut University